<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing of second-line antituberculosis drugs in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing of second-line antituberculosis drugs in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing of second-line antituberculosis drugs in children</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Daily pediatric dose</td> <td class="subtitle1">Usual maximum daily dose</td> <td class="subtitle1">Main and rare but serious adverse effects</td> </tr> <tr> <td>Amikacin*<sup>¶</sup></td> <td> <ul> <li>15 to 20 mg/kg IM or IV adjusted according to serum concentrations<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>1 g</li> </ul> </td> <td>Auditory and vestibular toxic effects, nephrotoxic effects</td> </tr> <tr class="highlight_gray_text"> <td>Amoxicillin-clavulanate</td> <td> <ul> <li>40 mg/kg given twice daily based on the amoxicillin component</li> </ul> </td> <td> <ul> <li>Dosed on amoxicillin component: Maximum 4 g per day</li> </ul> </td> <td>GI toxicity</td> </tr> <tr> <td>Bedaquiline</td> <td> <ul> <li>For children &lt;15 kg: Consult a specialist</li> <li>For children 15 to &lt;30 kg: 2 tabs (200 mg) daily for 2 weeks, then 1 tab (100 mg) 3 times/week (with at least 48 hours between doses) for 22 weeks</li> <li>For children ≥30 kg: 4 tabs (400 mg) daily for 2 weeks, then 2 tabs (200 mg) 3 times/week (with at least 48 hours between doses) for 22 weeks</li> </ul> </td> <td> </td> <td>QT prolongation, neurologic toxicities such as paresthesia, tremor, anxiety, depression, insomnia, tinnitus and blurred vision</td> </tr> <tr class="highlight_gray_text"> <td>Capreomycin (not available in United States; limited availability elsewhere)*<sup>¶</sup></td> <td> <ul> <li>15 to 30 mg/kg IM</li> </ul> </td> <td> <ul> <li>1 g</li> </ul> </td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections</td> </tr> <tr> <td>Clofazimine (not commercially available in the United States; requires application to FDA Division of Special Pathogen and Immunologic Drug Products; telephone <span class="nowrap_whitespace">301-796-1600)</span></td> <td> <ul> <li>2 to 5 mg/kg orally (optimal dose in children is unknown)</li> </ul> </td> <td> <ul> <li>300 mg</li> </ul> </td> <td>Red-grey discoloration of skin, eyes, body fluids, GI toxicity, photosensitivity, others</td> </tr> <tr class="highlight_gray_text"> <td>Cycloserine<sup>◊</sup></td> <td> <ul> <li>15 to 20 mg/kg orally in 1 dose or 2 divided doses</li> </ul> </td> <td> <ul> <li>1 g</li> </ul> </td> <td>Psychosis, personality changes, seizures, rash</td> </tr> <tr> <td>Delamanid</td> <td> <ul> <li>1 to 6 kg: Consult a specialist</li> <li>7 to 23 kg: 25 mg orally twice daily</li> <li>24 to 34 kg: 50 mg orally twice daily</li> <li>&gt;34 kg: 100 mg orally twice daily</li> </ul> </td> <td> <ul> <li>200 mg</li> </ul> </td> <td>QT prolongation, neurologic toxicities such as paresthesia, tremor, anxiety, depression, insomnia, tinnitus, and blurred vision</td> </tr> <tr class="highlight_gray_text"> <td>Ethionamide</td> <td> <ul> <li>15 to 20 mg/kg orally in 2 or 3 divided doses</li> </ul> </td> <td> <ul> <li>1 g</li> </ul> </td> <td>GI tract disturbances, hepatotoxic effects, hypersensitivity reactions, hypothyroidism</td> </tr> <tr> <td>Imipenem-cilastatin</td> <td> <ul> <li>§</li> </ul> </td> <td> <ul> <li>§</li> </ul> </td> <td>GI toxicity, seizures</td> </tr> <tr class="highlight_gray_text"> <td>Isoniazid, high dose</td> <td> <ul> <li>15 to 20 mg/kg orally, IM, or IV</li> </ul> </td> <td> <ul> <li>400 mg</li> </ul> </td> <td>Hepatitis, peripheral neuropathy (administer with pyridoxine), hypersensitivity, others</td> </tr> <tr> <td>Kanamycin*<sup>¶</sup></td> <td> <ul> <li>15 to 30 mg/kg IM or IV adjusted according to serum concentrations</li> </ul> </td> <td> <ul> <li>1 g</li> </ul> </td> <td>Auditory and vestibular toxic effects, nephrotoxic effects</td> </tr> <tr class="highlight_gray_text"> <td>Levofloxacin<sup>¥</sup></td> <td> <ul> <li>15 to 20 mg/kg orally or IV in 2 divided doses<sup>¥</sup></li> </ul> </td> <td> <ul> <li>750 mg<sup>¥</sup></li> </ul> </td> <td>Theoretical effect on growing cartilage, tendonitis, GI tract disturbances, cardiac disturbances, peripheral neuropathy, rash, headache, restlessness, confusion</td> </tr> <tr> <td>Linezolid</td> <td> <ul> <li>&lt;16 kg: 15 mg/kg orally or IV once daily</li> <li>&gt;16 kg: 10 to 12 mg/kg orally or IV once daily</li> </ul> </td> <td> <ul> <li>600 mg</li> </ul> </td> <td>Myelosuppression</td> </tr> <tr class="highlight_gray_text"> <td>Meropenem<sup>‡</sup></td> <td> <ul> <li>20 to 40 mg/kg IV in 3 divided doses; must be given with oral clavulanate (see amoxicillin-clavulanate above)</li> </ul> </td> <td> <ul> <li>6 g</li> </ul> </td> <td>GI toxicity, seizures</td> </tr> <tr> <td>Moxifloxacin<sup>¥</sup></td> <td> <ul> <li>10 to 15 mg/kg orally or IV<sup>¥</sup></li> </ul> </td> <td> <ul> <li>400 mg<sup>¥</sup></li> </ul> </td> <td>Theoretical effect on growing cartilage, tendonitis, GI tract disturbances, cardiac disturbances, peripheral neuropathy, rash, headache, restlessness, confusion</td> </tr> <tr class="highlight_gray_text"> <td>Para-aminosalicylic acid</td> <td> <ul> <li>200 to 300 mg/kg orally in 2 divided doses (some clinical centers give PAS 200 mg/kg as a single daily dose; this could be considered)</li> </ul> </td> <td> <ul> <li>12 g</li> </ul> </td> <td>GI toxicity, hepatotoxicity, hypothyroidism (treat with thyroid replacement)</td> </tr> <tr> <td>Streptomycin*<sup>¶</sup></td> <td> <ul> <li>20 to 40 mg/kg IM</li> </ul> </td> <td> <ul> <li>1 g</li> </ul> </td> <td>Auditory and vestibular toxic effects, nephrotoxic effects (which must be pre-emptively monitored) and rash</td> </tr> <tr class="highlight_gray_text"> <td>Thiacetazone<sup>†</sup> (not available in United States)</td> <td> <ul> <li>3 to 4 mg/kg orally</li> </ul> </td> <td> <ul> <li>150 mg</li> </ul> </td> <td>Stevens-Johnson syndrome in HIV-infected patients, GI intolerance, hepatitis, skin reactions</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Antituberculous agents are used in multidrug combination regimens of varying duration, which are described in detail in a separate table (refer to the UpToDate table on regimens for treatment of drug-susceptible tuberculosis) and in the accompanying text. The optimal dosing of many second-line drugs used to treat drug-resistant tuberculosis in children is not known. These drugs should be used in consultation with a specialist in tuberculosis.</li>
<li>Dosing of oral medications for treatment of multidrug-resistant or extensively drug-resistant tuberculosis should be daily, not intermittent.</li>
<li>Doses listed in this table are for patients with normal renal function; dose adjustment of many of these agents is needed in altered renal function.</li>
</ul></div><div class="graphic_footnotes"><p>IM: intramuscular; IV: intravenous; GI: gastrointestinal.</p>
<p>* Generally given five to seven times per week (15 mg/kg or a maximum of 1 g per dose) for an initial two to four months and then (if needed) two to three times per week (20 to 30 mg/kg or a maximum of 1.5 g per dose). Dose should be decreased if renal function is diminished. Amikacin is preferred to kanamycin in children. Since IM injection of amikacin is very painful, IV infusion is preferred.</p>
<p>¶ For patients who are overweight or obese, dose is based on adjusted dosing weight (refer to the UpToDate calculator). When available, serum drug monitoring is advised to establish optimal dosing.</p>
<p>Δ Note dose of amikacin may need to exceed 20 mg/kg to reach a therapeutic level in young children.</p>
<p>◊ When available, serum drug monitoring is advised to establish optimal dosing. Recommended peak (two to four hours post-dose) level is not higher than 30 microg/mL.</p>
<p>§ Experience with imipenem-cilastatin in children with drug-resistant TB is very limited.</p>
<p>¥ According to the American Academy of Pediatrics, fluoroquinolones should not be used routinely as first-line agents in children &lt;18 years old except when specific indications exist or in specific conditions for which there are no alternative agents and the drug is known to be effective for the specific situation.</p>
<p>‡ Dosing of meropenem in the setting of meningitis (in the absence of specific data for tuberculous meningitis) consists of 120 mg/kg in three divided doses.</p>
† Should not be used in patients with HIV because of the serious risk of life-threatening adverse effects.</div><div class="graphic_reference">Data from:
<ol>
<li>Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953.</li>
<li>World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva 2008.</li>
<li>World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. WHO, Geneva 2016.</li>
<li>World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. WHO, Geneva 2014.</li>
<li>Treatment Guidelines from The Medical Letter. The Medical Letter 2012; 10:29.</li>
<li>Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</li>
<li>World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. WHO, Geneva, 2016.</li>
<li>American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li>
<li>Harausz EP, Garcia-Prats AJ, Seddon JA et al. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. Am J Respir Crit Care Med 2017; 195:1300.</li>
<li><a href="http://sentinel-project.org/wp-content/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf" target="_blank">http://sentinel-project.org/wp-content/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf</a> Management of Drug-Resistant Tuberculosis in Children: A Field Guide. Boston, USA: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; November 2018, Fourth edition. (Accessed on March 26, 2019).</li>
</ol></div><div id="graphicVersion">Graphic 88543 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
